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ABSTRACT 
Background: The purpose of this study was to examine the differing perspectives and perceptual gaps relating 
to ulcerative colitis (UC) symptoms and their management between patients and healthcare professionals 
(HCPs). 
Methods: Structured, cross-sectional, Web-based questionnaires designed to assess a variety of disease 
indices were completed by adult patients with UC and HCPs involved in the care of patients with UC from 
Canada, France, Germany, Ireland, Spain, and the United Kingdom. 
Results: Surveys were completed by 775 patients, 475 physicians, and 50 nurses. Patient self-reported 
classification of disease severity revealed generally greater severity (mild, 32%; moderate, 53%) compared 
with physician and nurse estimates of UC severity among their caseloads (mild, 52% and 49%; moderate, 34% 
and 37%, respectively). Patients reported that an average of 5.5 (standard deviation, 11.0) flares (self-defined) 
occurred over the past year, compared with 3.4 and 3.8 flares per year estimated by physicians and nurses. 
Perceived flare triggers differed between patients (stress ranked first) and HCPs (natural disease course 
ranked first). Fifty-five percent of patients stated that UC symptoms over the past year had affected their 
quality of life, while physicians and nurses estimated that 35% to 37% of patients would have a reduced quality 
of life over the same period. Patients ranked urgency and pain as the most bothersome symptoms, while 
physicians and nurses ranked urgency and stool frequency highest. About half of patients (47%) defined 
remission as experiencing no symptoms; by comparison, 62% to 63% of HCPs defined remission as requiring 
the complete absence of symptoms. HCPs (doctors/nurses in general practice and/or hospital) were regarded 
by patients as their main source of UC information by 72%; however, 59% reported not arranging regular visits 
to see their HCPs. 
Conclusions: This large survey identified important differences between patients' and HCPs1 perceptions of 
the impact of UC symptoms on patients' lives. Notably, HCPs may underestimate the effect of specific UC 
symptoms on patients and may fail to recognize issues that are important to patients. 
 





Ulcerative colitis (UC) is an inflammatory disease of the large bowel currently thought to affect 120 to 200 per 
100,000 people throughout the Western world [1]. Manifesting clinically as a diverse range of relapsing-
remitting gastrointestinal and systemic symptoms, sufferers can find the management of their disease 
challenging, often resulting in reduced health-related quality of life and poor life satisfaction [2]. Although a 
number of differing treatments and management strategies are available [3-5], previous studies 
(predominantly based in the United States) have shown that patients' and physicians' perceptions and 
opinions regarding UC, its management, and specific therapies often differ [6,7]. In particular, the Ulcerative 
Colitis: New Observations on Remission, Management and Lifestyle (UC: NORMAL) survey observed that 
physicians tended to underestimate the burden of disease on patients, while many patients considered their 
symptoms/flares to be "normal" [7]. 
Following on from previous surveys, this study, conducted in 5 European countries and Canada, was designed 
to elucidate if any differences exist between patients living with UC and the healthcare professionals (HCPs) 
who provide treatment for such patients in their respective perceptions on living with UC. Notably, this study 
also explored the viewpoints of specialist nurses whose perspectives, despite regular involvement in the long-




Patients who participated in this online survey were aged >18 years and had a previous formal clinical 
diagnosis of UC (any severity). Patients were excluded if they had previously undergone a full or partial 
colectomy. Physicians were considered eligible for this study if they were experienced gastroenterologists or 
internal medicine (IM) physicians with a special interest in gastrointestinal medicine and were actively involved 
in the treatment and management of patients with UC. Nurses were considered eligible if they were specialists 
in inflammatory bowel disease (IBD) or gastroenterology and were actively managing patients with UC; all 
nurses were required to see a minimum of 20 patients with UC per month. Both physician and nurse 
respondents were excluded if: total clinical care/practice (not just on UC) occupied <50% of their normal 
workload; they did not personally consult patients with UC; they were engaged as a consultant or advisor to 
the pharmaceutical industry; or if they had qualified to practice within the last 2 (nurses) or 3 (physicians) 
years. 
All respondents provided their consent before completing the questionnaire and were remunerated on behalf 
of the investigators by the sponsor (Shire Pharmaceuticals LLC, Wayne, PA, USA) for their participation in the 
survey. 
Study design 
This was an Internet-based survey of patients with UC and practicing HCPs (gastroenterologists, IM physicians 
specializing in gastrointestinal medicine and IBD/ gastroenterology nurses) from 5 European countries 
(France, Germany, the Republic of Ireland, Spain, the United Kingdom) and Canada. All HCPs were involved in 
the treatment of patients with UC, although they were not required to be directly linked to the patients 
enrolled in this study. 
All respondents were pre-identified from patient and physician/nurse access panels or via custom "phone-to-
Web"   recruitment,   and   then   rescreened   using   the previously described criteria to confirm eligibility. For 
those respondents whose e-mail addresses were included in the access panel/sample lists, e-mail invitations 
including a link to the online survey were sent without any prior phone or personal contact. In cases where the 
panel or sample list included only phone numbers, respondents were called and asked for their e-mail 
addresses; a link to the respective survey was then sent while the respondent was on the phone (phone-to-
Web recruitment). All sampling was conducted as randomly as possible with full geographical dispersal within 
each of the countries. Patient advocacy groups and organizations were not used to recruit patients, so as to 
avoid potential bias by over-sampling patients who were likely to be more aware of their condition and 
perhaps more actively engaged with UC management. The market research conducted was fully compliant 
with the British Healthcare Business Intelligence Association (BHBIA) Legal and Ethical Framework for 
Healthcare Market Research, which provides best practice guidelines for healthcare market research within an 
up to date legal and ethical framework. According to these guidelines, market research "falls outside the remit 
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of the Research Governance Framework and does not require Research Ethics Committee approval" [8]. Local 
market research guidelines were taken into consideration in the countries outside of the United Kingdom 
where patients were surveyed. 
Survey tool 
To record respondents' opinions and perceptions of UC and its management, three structured, cross-sectional, 
self-administered, computer-aided Internet-based questionnaires were prepared by GfK HealthCare (London, 
United Kingdom), a market research company, with input from the study sponsor (Shire Pharmaceuticals 
LLC). The questionnaires were developed for patients, physicians, and nurses, respectively, based primarily on 
the previously reported US UC: NORMAL Internet survey questionnaire [7,9]. The questionnaires were piloted 
on a mix of 13 physicians, nurses, and patient respondents in the UK and Canada in May of 2010. The survey 
design was reviewed and finalized by a purpose-assembled working group of UC experts, including SS, JP and 
EL. 
The three survey questionnaires included questions to assess multiple aspects of UC and its management 
including: symptoms experienced; perceptions of remission; the impact of UC on patient quality of life; and 
relationships between treating physicians and patients (Additional file 1, Additional file 2 and Additional file 3). 
Definitions for specific terms within the surveys, such as "normal" or "flare" were not provided to respondents, 
but were defined by respondents themselves based on their own perceptions. Symptom scores were based on 
a scale of 0 to 10, with higher scores relating to greater severity. Physicians and nurses were asked to evaluate 
UC in the context of all patients with UC that they were currently treating. 
The patient, physician, and nurse questionnaires comprised 64, 44, and 49 main questions each and were 
estimated to take 30, 24, and 30 minutes to complete, respectively. Before being administered to the whole 
study population, all three questionnaires were piloted and tested in two central locations by 13 HCP and 
patient respondents to ensure that items were correctly understood and key issues covered appropriately. 
Seven respondents tested the pilot questionnaires on May 13, 2010, in the United Kingdom; six more tested 
them on May 17, 2010, in Canada. No major modifications were made to any of the questionnaires after the 
pilot testing; however, minor changes were made to the wording of some questions to ensure they would be 
understood correctly. The surveys were translated into the native language for each country. 
Analysis 
The primary aim of this study was to assess patients' and HCPs' differing perceptions of UC and its associated 
treatment. The results of a separate analysis of the survey data, which aimed to explore national differences in 
patients' experiences, expectations, and beliefs about UC and its management, will be published elsewhere. 
Prior to analysis, all responses were checked by GfK HealthCare for sense, quality, consistency, and reliability. 
No quality issues were identified for this study. With regard to statistical accuracy, for patients, a range of 
±3.3% to ±7.6% (at 95% confidence interval [CI] limits; survey percentage, 5%-50%) was calculated at the 
individual country level, assuming 150 respondents per country; likewise, a statistical accuracy range of ±5.9% 
to ±13.6% (at 95% CI limits) was determined if 50 patient respondents per country were assumed. For 
physicians, a statistical accuracy range of ±4.1% to ±9.5% was calculated at the individual country level, 
assuming 100 respondents per country. Comparisons drawn between groups (eg, patients and physicians) are 




Surveys were completed by 775 patients, 475 physicians, and 50 nurses between June 10, 2010, and August 20, 
2010, in Canada, Germany, Ireland, Spain, and the United Kingdom, and between January 20, 2010, and 
February 24, 2011, in France. Among patients who completed questionnaires, 150 each were submitted by 
patients in France, Germany, Spain, and the United Kingdom,  125 were submitted in Canada,  and 50 in 
Ireland. Patient response rates (RR) were not calculated, as different methods of recruitment were used across 
countries. Completed surveys were submitted by 100 physicians each in France (RR 18%), Germany (RR 23%), 
Spain (RR 17%), and the United Kingdom (RR 19%), 60 in Canada (all gastroenterologists; RR 6%), and 15 in 
Ireland (RR 12%). Fifty nurses (RR 15%) completed surveys, all of whom were based in the United Kingdom. 
Demographic and baseline data for all patient, physician, and nurse respondents are shown in Table 1. A 
majority of patients were female and approximately half were married; 59% were in full- or part-time 
employment. Comorbidities present in >10% of patients included chronic back pain, migraine, arthritis, 
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depression, and asthma. Approximately half of patients were symptomatic at the time of the survey and just 
over three-quarters were currently taking prescription medication for their UC; 5-aminosalicylic acid (5-ASA) 
was the most commonly prescribed UC medication (75%), followed by corticosteroids (32%), 
immunosuppressants (24%), and biological therapies (anti-tumor necrosis factor agents or other; 15%). 
Overall, physicians surveyed (gastroenterologists, 82%; internal medicine physicians, 18%) tended to be male 
and were working predominantly in city-based, public teaching hospitals. Surveyed physicians devoted a 
mean (standard deviation [SD]) of 87% (11%) of their working day to clinical practice, and saw a mean (SD) of 
35 (33) patients with UC in a typical month. Nurses were predominately female (92%), most were clinical nurse 
specialists (84%), and a mean (SD) of 81% (14%) of their day was devoted to direct patient care. 
Perceptions of UC symptoms 
Physicians assessed UC among their caseloads to be less severe compared with the overall profile of UC 
patients' self-reported disease severity (Figure 1). Overall, 32%, 53%, and 15% of patients described 
themselves as having mild, moderate, and severe UC, respectively. In contrast, physicians estimated their UC 
caseloads to be comprised of a mean (SD) of 52% (19%) mild cases, 34% (14%) moderate cases, and 15% (12%) 
severe cases, respectively. Nurses' estimates of their UC caseloads were similar to those of physicians: mean 
(SD) of 49% (22%) mild, 37% (17%) moderate, and 15% (9%) severe. Patients were not paired with their HCP; 
thus it is not known if HCP and patient descriptions of UC severity agreed for any individual patient. When 
patients were questioned about how they felt their own physician perceived their disease, 8% were unsure. Of 
those who had a clear opinion, the resulting profile of patients' perception of their physicians' severity ratings 
was almost identical to that of patients' self-reported UC severity (mild, 33% vs 32%; moderate, 53% vs 53%; 
severe, 14% vs 15%; respectively). 
There were also differences in perception among patients, physicians, and nurses in terms of what was most 
bothersome to patients about their UC (Figure 2). Urgency and pain were most frequently ranked as the most 
bothersome symptom by patients (30% and 25%, respectively). For physicians and nurses, urgency (36% and 
58%, respectively) and stool frequency (34% and 22%, respectively) were most frequently ranked as most 
bothersome. Pain was ranked as most bothersome by only 11% and 6% of physicians and nurses, respectively. 
 





Male, % 37 
Median age, year (SD) 44.6 (15.1) 
National patient organization member, % 10 
 Marital status, %  
Single, no partner 25 
Single, with partner 26 
Married 49 
 Employment, %  
Full-time 43 
Part-time 16 
 Comorbidity ≥10% incidence, %  





 UC status, %  
In flare 11 
Mildly symptomatic 43 
In remission 46 
Currently receiving UC therapy, % 76 














Male, % 82 
Mean qualification year (SD) 1992 (9.1) 
 Primary specialty, n  
Gastroenterology 82 
nternal medicine 18 
Lower GI/IBD specialist, % 68 




 Location, %  
City center 71 
Suburban 23 
Rural 6 
Teaching hospital, % 67 
 Type of hospital, %  
Public 89 
Private 11 
Mean % of working day devoted to 874 (11.2) 
clinical practice (SD)  
Mean number of patients with UC seen 35.2 (33.0) 
in typical month, n (SD)  
Nurses  
N 50 
Male, % 8 
Mean year of qualification (SD) 1992 (7.5) 
Mean year becoming IBD Nurse (SD) 2003 (3.8) 
 Type of nurse  
Nurse practitioner 10 
Nurse prescriber 6 
Clinical nurse specialist 84 
 Location, %  
City center 56 
Suburban 40 
Rural 4 
Teaching hospital, % 80 
Mean % of working day devoted to 80.8 (14.1) 
direct patient care (SD)  
Mean number of patients with UC 66.6 (40.2) 
seen in typical month, n (SD)  
Percentage of nurses who make treatment 86 
decisions for patients with UC  
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Percentage of nurses who are qualified 44 
nurse prescriber  
Percentage of nurses who write 5-ASA 77 
prescriptions for mild-to-moderate UC  
Mean number of 5-ASA prescriptions 214 (15.9) 
written per month (SD)  
HCP, healthcare professional; SD, standard deviation; UC, ulcerative colitis; 
5-ASA, 5-aminosalicylic acid; Gl, gastrointestinal; IBD, inflammatory bowel 
disease. 
*AII patients currently taking prescription medication for their UC. 
+
lmmunomodulator or immunosuppressant. 
 
 
Figure 1 UC severity ratings. Patients' seIf-reported classification of disease severity: patients were asked how 
they would personally describe the severity of their UC overall, regardless of how their doctor described it. 
Physicians' and nurses' assessment of symptom severity among their caseloads: physicians and nurses were asked 
what percentage of their current UC patients had mild, moderate, or severe disease. Data may not add up to 




Beliefs and perceptions surrounding UC flares 
Physician and nurse estimates of the typical mean (SD) number of flares per year experienced by a patient 
with UC were lower (3.4 [3.0] and 3.8 [8.0], respectively) than patients' estimates of the mean (SD) number of 
UC flares that they experienced (5.5 [11.0]). Approximately two-thirds of patients (68%) considered the 
number of flares they had experienced during the past 12 months to be normal; these patients reported a 
mean (SD) of 3.9 (5.2) flares, while those who considered the number of flares they had experienced to be 
abnormal reported a mean (SD) of 5.5 (8.1) flares. Out of these 5.5 flares/year experienced, patients reported 
discussing a mean (SD) of 4.2 (7.1) of them with their primary HCP. The most common reasons patients gave 
for not discussing flares with their doctor or nurse were: "some attacks were milder/not too bad/cleared up 
quickly" (23%), "dealt with/managed it on my own/learned how to deal with it/ self management" (21%) and 
"settled/managed it on my own using (prescribed/self) medication" (17%). 
When asked to rate symptom severity during a flare on a continuous rating scale, patients' ratings were higher 
(more severe) than those estimated by HCPs on frequency of stools, frequency of blood in stools, and urgency 
(Figure 3). When asked to rank-order the most common causes of flare among "natural course of the 
condition," "changes from regular diet," "stress," and "not taking preventative   therapy,"   the   rank   orders   
differed   between patients and both physicians and nurses (Figure 4). Compared with patients, a higher 
percentage of physicians and nurses, respectively, ranked "natural disease course" followed by "not taking 
preventative therapy" as the most common causes. By contrast, patients ranked "stress" as the most likely 
trigger of UC flares. 
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Perceptions of remission 
Nearly half (47%) of all patients surveyed stated that remission realistically involved "experiencing no 
symptoms and feeling similar to how I did before I developed UC"; all but 2% of the remaining patients 
believed that they could be in remission while still experiencing some symptoms. According to their own 
estimates, patients who stated that remission involved "living without symptoms" experienced a lower 
average number of flares during the past 12 months compared with those who stated that remission involved 
"living with some symptoms" (4.2 vs 8.2 flares per year, respectively). 
Compared with patient expectations of remission, an even greater percentage of physicians (63%) and nurses 
(62%) agreed that remission required the "complete absence of symptoms" (Table 2). However, the physician 
survey probed deeper into HCP considerations of remission than the patient survey. Both physicians and 
nurses favored "normalized" endoscopy and quality of life, respectively, rather than "improved" endoscopy 
and quality of life as requirements of UC remission. The majority of physicians and nurses considered patient 
satisfaction with outcome, an absence of inflammatory markers, and becoming steroid-free as necessary 
requirements when defining remission (Table 2). Approximately 4 in 10 physicians and nurses recognized that 
patient definitions of remission were less stringent than their own, compared with nearly 2 in 10 HCPs who 
believed that patient definitions of remission were more stringent. 
Burden of disease and perceived disease control 
When asked to determine how well UC was controlled over the past year, 55% of patients responded that 
symptoms of UC caused at least some disruption to their quality of life; physicians and nurses perceived UC as 
affecting quality of life in only 35% to 37% patients, respectively (Figure 5). In addition, a lower percentage of 
patients (26%) considered UC symptoms to be completely or mostly under control compared with the 
perceptions of physicians (43%) or nurses (40%). A large proportion of patients strongly agreed (49%) or 
somewhat agreed (38%) that they were worried about the long-term health effects of having UC. 
 
Figure 2 Most bothersome factor for UC patients, as assessed by patients, physicians, and nurses. Patients were 
asked which one of the following bothered them the most about their UC: urgency, pain, number of stools per day, 
blood in your stools, number of tablets to be taken, or none of the above. Physicians and nurses were asked which 
one of the same choices they thought bothered their UC patients the most. Data may not add up to 100% due to 
rounding. UC, ulcerative colitis. 
 
 
Beliefs and perceptions about treatment with 5-ASA 
Three-quarters of patients (75%) were currently receiving a 5-ASA for the treatment of their UC; 58% of those 
using 5-ASA were taking it as monotherapy. The overall percentage of patient self-reported adherence with 
prescribed oral 5-ASA therapy during their most recent period of remission (67%) was slightly higher than 
physicians' (62%) and nurses' (57%) estimates of adherence among their caseloads. Among the non-adherent 
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patients, 47% had tried not taking their medication at all for a period of time and 53% tried taking less than 
what was prescribed. Over a third of non-adherent patients (38%) either did not reveal (20%) or under-
reported (18%) the extent of their non-adherence to their HCP. When asked to think about the last 7 days, 53% 
of patients stated that they had taken less than their prescribed dose of 5-ASA, with 5% not taking any 
medication at all. 
The majority (78%) of patients were "very" or "somewhat" satisfied with 5-ASA treatment, consistent with 
physicians' perception of patient satisfaction (physicians estimated that 90% of their patients were "very" or 
"somewhat" satisfied). Among dissatisfied patients, only 35% discussed their dissatisfaction with their doctor. 
Ninety-one percent of patients currently receiving oral 5-ASA therapy reported that they would be willing to 
switch to a once-daily formulation of 5-ASA during disease remission if their doctor suggested it. However, 
30% of physicians said that they were unlikely to offer a once-daily oral 5-ASA to a patient in remission 
currently taking oral 5-ASA twice daily. 
Relationship between patients and HCPs 
Almost three-quarters of patients (72%) ranked doctors and/or nurses at their general practice/surgery or 
hospital among their top three sources of information about UC and the different treatment options available, 
and 45% reported UC-related Web sites as another top source. Despite this, 56% stated that they did not see 
their doctor or specialist nurse on a regular basis, and another 3% stated that they never visit their doctor or 
specialist nurse. The remaining patients stated that they visited their main HCP when feeling unwell or having 
a flare-up (29%), or only if experiencing a serious flare (27%). Notably, 64% of patients expressed that they 
had never taken the initiative to ask their doctor about new medications and treatment options for UC. 
While 69% of patients considered themselves to be completely open with their doctor about their UC during 
consultations, another 21% considered themselves open only if carefully questioned; the remaining patients 
admitted keeping information from their physician. Male and female patients appeared to be equally open to 
discussion of their UC during healthcare visits, with 68% and 69%, respectively, describing themselves as 
being completely open. Among the 40% of physician respondents who shared patient management with 
nurses, accessibility to patients (70%) and having more time to spend with patients (44%) were ranked as the 
top strengths of the care provided by nurses, suggesting that physicians perceived nurses as a potential 
resource for improving communication with patients. 
 
Figure 3 Mean symptom ratings during a flare in mild-to-moderate UC, as assessed by patients, physicians, and 
nurses. Patients with τiild-to-moderate disease were asked to rate each of the following to describe a typical flare 
of UC on a continuous rating scale: frequency of stools per day, frequency of blood in stools, and feeling of urgency 
to go to the bathroom. Physicians and nurses were asked to rate the same choices according to how they would 
define a typical flare experienced by a mild-to-moderate patient. Ratings were transformed to a 10-point scale; 
higher scores indicated greater symptom severity. UC, ulcerative colitis. *Based on mild-to-moderate cases only. 
 
 
Figure 4 Most likely cause of UC flares, as ranked by patients, physicians, and nurses. Patients, physicians, and 
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nurses were asked, based on their own viewpoint, to place the following four causes of UC flare in rank order: 
stress, natural course of the condition, changes from regular diet, and not taking maintenance therapy when UC is 




This survey provides insight into the differing experiences and perceptions of patients with UC and HCPs 
involved in the management of such patients across Western Europe and Canada. To our knowledge, this is 
the first international study in UC to compare the views and beliefs of patients, physicians, and specialist 
nurses. 
A higher percentage of patients reported that UC symptoms adversely affected their quality of life compared 
with the percentage of patients perceived by HCPs to have quality of life disruptions. Furthermore, a majority 
of patients assessed their own symptoms to be moderate in severity, while HCPs estimated the majority of 
their patients as having UC of mild severity. These results suggest that physicians and nurses may 
underestimate patients' symptom burden. Our data also demonstrated a gap among patients and HCPs with 
regard to what bothers patients most about their UC. Whereas patients most frequently ranked urgency, pain, 
and bloody stools as bothersome factors relating to their UC, HCPs perceived urgency and stool frequency as 
being most bothersome. This discordance suggests that physicians and nurses may need to be more aware of 
patients' feelings in regards to level of pain and bloody stools; it should be noted that a relatively high 
prevalence of chronic pain as a patient comorbidity at baseline (15%) may have influenced the results. 
Physicians' and nurses' estimates of the annual incidence of flares experienced by a patient with UC were 
lower than the patient-reported number of UC flares. A similar finding was reported from the UC: NORMAL 
survey [7], suggesting either a potential underestimation of patients' symptoms by HCPs, or a 
misinterpretation of symptoms by patients. In addition, patients in this study only discussed approximately 
three-quarters of their experienced flares (self-defined) with their HCP. This patient-physician gap suggests a 
need for more open lines of communication and improved patient education on symptom evaluation, so that 
patients will be better able to define when a flare is occurring. 
Approximately half of patients defined remission as the complete absence of symptoms compared with 62% 
to 63% of nurses and physicians, respectively. This discrepancy is not unexpected given that there is no widely 
agreed upon definition of UC remission. At present, discussions are unfolding among HCPs about how best to 
define remission; definitions in clinical trials may be less stringent (ie, some UC symptoms are acceptable) 
compared with the expectations of clinicians in daily practice noted in this survey. The initiation of a discussion 
among patients, HCPs, and regulatory authorities on modifying endpoints for new UC medications being 
developed would be helpful. 
 
Table 2 Necessary personal requirements of remission, as selected by physicians and nurses 
Remission requirements (%) Physicians Nurses 
Reduced symptoms 36 38 
OR   
Complete absence of symptoms 63 62 
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Normalized endoscopy score 50 64 
OR   
mproved endoscopy score 45 34 
Quality of life-normalized 64 62 
OR   
Quality of life-improved 35 38 
Patient appears content with 72 80 
treatment outcome   
No laboratory indicators of 
inflammation, 
69 54 
such as C-reactive protein   
Absence of steroids 60 70 
Physicians and nurses were asked, based on their personal definitions, to select the requirements for remission from three 
paired options (symptoms, endoscopy score, quality of life) and three unpaired options. Respondents could only select one 
option for each of the paired options, but could also select any or none of the remaining three options. 
 
Figure 5 Disease control over the past 12 months, as assessed by patients, physicians, and nurses. Patients were 
asked which one of the following statements best described how effectively their UC had been controlled over the 
past 12 months: (1) my symptoms were completely or mostly under control; (2) my symptoms were present but did 
not interfere with my quality of life; (3) my symptoms caused some disruption to my quality of life; or (4) my 
symptoms affected my quality of life on a regular basis. Physicians and nurses were asked, in terms of how 
effectively their UC had been controlled over the last 12 months, approximately what percentage of your mild-to-




Patients were more likely than HCPs to rank stress and diet as the most likely triggers of flares, whereas 
HCPs were more likely to rank the natural disease course and not taking maintenance therapy as the most likely causes. It 
may be the case that patients are unaware of the relapsing-remitting nature of the disease [10], and the importance of 
maintenance therapy during quiescent periods to reduce the probability of a disease flare [11-13]. If patients are not 
regularly taking maintenance therapy, flare recurrence is more likely [11,13,14], and may subsequently be attributed to 
causes such as stress and diet; therefore, patient education on UC disease course and medication adherence is critical. It is 
also possible that patients may have misinterpreted symptoms as UC flare, instead of symptoms of irritable bowel 
syndrome (IBS). Both conditions share some common symptoms such as pain and alteration of bowel habits [15], in part 
because of the role of gut microbiota in the pathogenesis of both UC and IBS. Therefore, a better understanding and 
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distinction of UC versus IBS symptoms is important for proper management of UC. 
Patients' estimates of adherence with current oral 5-ASA therapy during their most recent period of remission were 
broadly similar to HCPs' estimates. However, patient-estimated adherence rates over the past 7 days were lower. Similar 
to rates observed in previous observational data [6,7,11,12,14,16-20], these low adherence rates are troublesome, given 
that poor adherence with 5-ASA therapy is linked to an increased risk of flare and higher medical costs [11-13,21]. In turn, 
increased disease activity can also result in deterioration of patient quality of life [2,22-24]. Effective patient-physician 
communication and collaboration has been shown to improve adherence in other chronic diseases [25,26], and may 
improve adherence rates for patients with UC. 
About 20% of patients reported being dissatisfied with 5-ASA treatment while physicians perceived that only 10% of 
patients were dissatisfied. However, only about one-third of dissatisfied patients reported having discussed their concerns 
with their doctor. Thus, more direct questioning from HCPs may help patients be more forthcoming. Furthermore, 
although the large majority of patients (72%) saw their doctor or specialist nurse in general practice and/or hospital as the 
principal source of information about their UC and its treatment, most (59%) did not arrange regular visits. This lack of 
regular contact between patients and their HCP may account, in part, for the discrepancies in perception of the impact of 
UC. 
One unique aspect of this survey is that it compares the perception of nurses treating UC with physicians. Given that the 
sample of nurse specialists was limited to the United Kingdom, it may be of benefit to specifically compare how the 
responses of UK nurses compared to those of UK physicians. Results from physicians and patients by country are 
presented in a separate analysis [27], although nurses were not included in that analysis. Briefly, for caseload severity, 
effect of UC on quality of life, and adherence to 5-ASA treatment, estimates of UK nurses and UK physicians were nearly 
identical (within 5 percentage points). The rank order of which UC symptoms were most bothersome to patients was the 
same for UK nurses and UK physicians (urgency, number of stools, blood in stools, and pain). However, UK nurse estimates 
of flares experienced per year were higher than UK physician estimates for each severity grade (mild, 1.6 vs 0.9; moderate 
3.4 vs 2.4; severe, 6.4 vs 4.4). Although it remains unclear how generalizable the nurse data are across nations, the UK data 
suggest that responses from nurses are likely to be similar to those of physicians from the same country. 
As with all observational studies, this study was subject to a number of limitations. The primary limitation was the fact that 
patients and HCPs were recruited independently and not matched; thus, it is possible that the patient respondents had a 
more severe disease profile compared with patients included in physicians' and nurses' caseloads. Additionally, patients 
and HCPs were not given standard definitions of disease severity or flares on which to base their responses. Nonetheless, 
the current findings are in line with that reported in the UC: NORMAL study [7]; the demographic profile of patient 
respondents was similar to that reported in previous surveys [7,9,28-30] and within the general UC patient population 
[28,31-33], suggesting that these results may be applicable to the larger UC population. 
 
CONCLUSIONS 
In conclusion, results of this European and Canadian survey demonstrate discordance between patients' self-
perceived experience with UC and HCPs' (physicians and nurses specializing in gastrointestinal medicine) 
estimates of UC disease burden. These differences could be addressed through improved communication 
between patients and their physician or specialist nurse (including more regular visits), and better patient 
education. As patients with other gastrointestinal chronic diseases may have similar experiences to those 
surveyed in this study regarding disease treatment and management, the findings reported here may also be 
more widely applicable. 
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